ORCHARD THERAPEUTICS PLC [●] American Depositary Shares, representing [●] Ordinary Shares Underwriting AgreementUnderwriting Agreement • June 3rd, 2019 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledJune 3rd, 2019 Company Industry JurisdictionOrchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] American Depositary Shares (“ADSs”), representing [●] ordinary shares, nominal value £0.10 per share (the “Ordinary Shares”), of the Company (the “Underwritten ADSs”) and, at the option of the Underwriters, up to an additional [●] ADSs, representing [●] Ordinary Shares (the “Option ADSs”). The Underwritten ADSs and the Option ADSs are herein referred to as the “Offered ADSs.” The Ordinary Shares represented by the
DEPOSIT AGREEMENTDeposit Agreement • March 22nd, 2019 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 22nd, 2019 Company Industry JurisdictionDEPOSIT AGREEMENT, dated as of November 2, 2018, by and among (i) Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
ORCHARD THERAPEUTICS PLC AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE ORDINARY SHARE (NOMINAL VALUE £0.10 PER SHARE) SALES AGREEMENTSales Agreement • February 28th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 28th, 2020 Company Industry JurisdictionOrchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
DEPOSIT AGREEMENT by and among ORCHARD THERAPEUTICS PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of [●], 2018Deposit Agreement • October 23rd, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 23rd, 2018 Company Industry JurisdictionDEPOSIT AGREEMENT, dated as of [●], 2018, by and among (i) Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • October 6th, 2022 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledOctober 6th, 2022 Company Industry JurisdictionThis Amended and Restated Employment Agreement (“Agreement”) is made by and between Orchard Therapeutics plc (the “Parent”), Orchard Therapeutics North America (the “U.S. Subsidiary”), and Frank Thomas (the “Executive”), and is effective as of October 4, 2022 (the “Effective Date”). The Parent, the U.S. Subsidiary, and their respective subsidiaries and other affiliates are collectively referred to herein as the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition.
ORCHARD THERAPEUTICS PLC and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES OUTSTANDING UNDER THE TERMS OF THE DEPOSIT AGREEMENT, DATED AS OF November 2, 2018 Amendment No. 1 to the Deposit Agreement...Deposit Agreement • March 14th, 2023 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 14th, 2023 Company Industry Jurisdiction
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF...Licence and Development Agreement • October 4th, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances) • England
Contract Type FiledOctober 4th, 2018 Company Industry Jurisdiction
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF...License Agreement • October 4th, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances) • California
Contract Type FiledOctober 4th, 2018 Company Industry JurisdictionNOW, THEREFORE, the Parties, in consideration of the mutual covenants and undertakings contained herein and for other good and valuable consideration including the share subscription by UCLB (for and on behalf of both UCLB and UCLA), intending to be legally bound, HEREBY AGREE as follows:
DIRECTOR NOMINATION AGREEMENTDirector Nomination Agreement • October 23rd, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances)
Contract Type FiledOctober 23rd, 2018 Company IndustryTHIS DIRECTOR NOMINATION AGREEMENT is dated as of October 18, 2018 (this “Agreement”), by and between Orchard Rx Limited (which will re-named and re-registered as a public limited company prior to the IPO (as defined below) at which point the company will be named Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and Glaxo Group Limited, a company incorporated under the laws of England (“GSK”), and is effective as of, and conditioned upon, the closing of the Company’s initial public offering (“IPO”) of American Depository Shares (“ADSs”), each ADS representing one ordinary share of the Company, on the Nasdaq Stock Market (the “Effective Date”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF...Asset Purchase and License Agreement • October 23rd, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances)
Contract Type FiledOctober 23rd, 2018 Company Industryeach a “party” and, together, the “parties”. Save as where otherwise provided, Glaxo Group and GSK IPD shall be jointly referred to as the “Seller”.
DATED JANUARY 19, 2018 NEW CONNECT INVESTMENTS LIMITED AND ORCHARD THERAPEUTICS LIMITED LEASE OF 2nd and 3rd FLOOR, 108 CANNON STREET, LONDON Lewis Silkin LLP Clifford’s Inn London EC4A 1BL (Ref: EMH8296/112671.14)Lease Agreement • October 4th, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances)
Contract Type FiledOctober 4th, 2018 Company Industry
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING...Research and Development Collaboration and License Agreement • October 23rd, 2018 • Orchard Rx LTD • Biological products, (no disgnostic substances) • England
Contract Type FiledOctober 23rd, 2018 Company Industry JurisdictionThis RESEARCH, DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of October 15th, 2010 (the “Effective Date”) by and between (a) Fondazione Telethon, having a registered office at via Carlo Spinola, 16, 00154, Rome, Italy (“F. Telethon”), and Fondazione Centro San Raffaele del Monte Tabor, having a registered office at Via Olgettina 60 20132 Milano (“F. San Raffaele”), each entity, a not-for-profit corporation incorporated under the laws of Italy, (F. Telethon and F. San Raffaele are hereinafter referred to jointly as “TELETHON-HSR”) on the one hand; and, (b) on the other hand, Glaxo Group Limited, a company incorporated under the laws of England and Wales with registered number 00305979, whose registered office is Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). TELETHON-HSR and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • February 27th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledFebruary 27th, 2020 Company Industry JurisdictionThis Employment Agreement (“Agreement”) is made by and between Orchard Therapeutics plc (the “Parent”), Orchard Therapeutics North America, a California corporation (the “U.S. Subsidiary”), and Frank Thomas (the “Executive”), and is effective upon the date it is fully executed (the “Effective Date”). The Parent, the U.S. Subsidiary, and their respective subsidiaries and other affiliates are collectively referred to herein as the “Company,” and the duties of the Company set forth in this Agreement may be discharged by any entity within that definition. Except with respect to the Equity Documents and subject to Section 10 below, this Agreement fully supersedes and replaces in all respects all prior agreements between the parties regarding the subject matter herein, including without limitation (i) the offer letter between Orchard Therapeutics Limited (a subsidiary of the Parent) and the Executive dated January 12, 2018 and (ii) any other offer letter, employment agreement or severance ag
INCENTIVE SHARE OPTION AGREEMENT UNDER THE ORCHARD THERAPEUTICS PLC 2018 SHARE OPTION AND INCENTIVE PLANIncentive Share Option Agreement • February 27th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledFebruary 27th, 2020 Company IndustryPursuant to the Orchard Therapeutics plc 2018 Share Option and Incentive Plan as amended through the date hereof (the “Plan”), Orchard Therapeutics plc (the “Company”) hereby grants to the Optionee named above an option (the “Share Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of Shares specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
Re: First Amendment to the Transitional Services AgreementTransitional Services Agreement • March 30th, 2022 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 30th, 2022 Company Industry JurisdictionAs we have discussed, this First Amendment to the Transitional Services Agreement (the “Amendment”) confirms the agreement between you, Orchard Therapeutics plc (the “Parent”) and Orchard Therapeutics North America (the “U.S. Subsidiary”, and together with the Parent, the “Company”), to amend the Transitional Services Agreement dated November 3, 2021 (the “Agreement”) to reflect, among other terms, that the mutually agreeable effective date of your resignation without Good Reason from the Company is December 31, 2022 (or such other date consistent with the terms of the Agreement as revised herein). The Agreement is attached hereto as Exhibit A to this Amendment. Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in the Agreement. For good and valuable consideration, the receipt of which is hereby acknowledged, you and the Company hereby agree as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 6th, 2023 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 6th, 2023 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of March 6, 2023 (the “Effective Date”), among Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and collectively the “Purchasers”).
MANUFACTURING AND TECHNOLOGY DEVELOPMENT master AGREEMENT July 2nd, 2020 Between Orchard Therapeutics (Europe) Limited and MolMed S.p.A.Manufacturing and Technology Development Master Agreement • August 6th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledAugust 6th, 2020 Company IndustryTHIS MANUFACTURING AND TECHNOLOGY DEVELOPMENT MASTER AGREEMENT (the “Agreement”) is entered into and made effective as of July 2nd, 2020 (the “Effective Date”)
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 20th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 20th, 2020 Company Industry JurisdictionThis First Amendment to Employment Agreement (this “Amendment”) is entered into and effective as of March 18, 2020 (the “Effective Date”), by and between Orchard Therapeutics plc (the “Parent”), Orchard Therapeutics North America, a California corporation (the “U.S. Subsidiary”) and Frank Thomas (the “Executive”). The Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates are collectively referred to herein as the “Company,” and the duties of the Company as set forth in this Amendment may be discharged by any entity within that definition.
Offer for Orchard Therapeutics plc (the “Company”)Acquisition Agreement • October 5th, 2023 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledOctober 5th, 2023 Company IndustryI, the undersigned, understand that the Purchaser is considering the Acquisition substantially on the terms and conditions set out or referred to in a draft of the transaction agreement, a copy of which is annexed hereto (the “Transaction Agreement”), and/or on such other terms and conditions as may be required any relevant securities exchange or as may be agreed in writing between the Purchaser and the Company. Capitalized terms used but not defined herein shall have the meaning set forth in the Transaction Agreement.
Re:Transitional Services AgreementTransitional Services Agreement • November 4th, 2021 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledNovember 4th, 2021 Company Industry JurisdictionThis letter confirms that you have resigned without Good Reason your employment with Orchard Therapeutics plc (the “Parent”) and Orchard Therapeutics North America (the “U.S. Subsidiary”, and together with the Parent, the “Company”), and that the Company has accepted such resignation, with a mutually agreeable effective date of April 1, 2022 (or such other date consistent with the terms set forth below). The Company appreciates your service and would like to make this transition as smooth as possible. To that end, this letter reflects the arrangement (the “Agreement”) discussed by you and the Company that allows you to remain employed by the Company until April 1, 2022 (unless your employment ends on an earlier date which can only happen if it is consistent with the terms set forth below or if you and the Company agree in writing to extend it to a later date), after which you will be eligible for the Health Benefits, the 2022 Prorated Bonus and the Extended Exercise Period set forth in
CERTAIN CONFIDENTIAL INFORMATION MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Manufacturing and Technology Development Master Agreement • March 14th, 2023 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledMarch 14th, 2023 Company IndustryThis amendment is effective as of the date the last signature is made ("Effective Date") between Orchard Therapeutics (Europe) Limited, with registered offices 245 Hammersmith Road, 3rd Floor, London, W6 8PW, United Kingdom England, company number 09759506, (OTL) and AGC Biologics S.p.A. with registered offices at via Meucci 3, Bresso (MI) Italy (AGC)
CONTRACT OF EMPLOYMENTContract of Employment • February 27th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledFebruary 27th, 2020 Company Industry JurisdictionThis Contract of Employment (“the Contract”) includes the particulars of employment required under Section 1 of the Employment Rights Act 1996 (as amended).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 9th, 2021 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledFebruary 9th, 2021 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of February 4, 2021 (the “Effective Date”), among Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on Exhibit A attached hereto (each a “Purchaser” and collectively the “Purchasers”).
DATED 17 MARCH 2020Settlement Agreement • March 20th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledMarch 20th, 2020 Company Industry Jurisdiction
ORCHARD THERAPEUTICS PLC AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE ORDINARY SHARE (NOMINAL VALUE £0.10 PER SHARE) SALES AGREEMENTSales Agreement • October 6th, 2022 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 6th, 2022 Company Industry JurisdictionOrchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), confirms its agreement (this “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”), as follows:
Amendment LetterFacilities Agreement • May 7th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledMay 7th, 2020 Company Industry
FIFTH AMENDMENT OF THE LICENCE AND DEVELOPMENT AGREEMENT BETWEENLicence and Development Agreement • May 7th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • England
Contract Type FiledMay 7th, 2020 Company Industry JurisdictionThis fifth amendment of the licence and development agreement (the "Fifth Amendment") is made this 3rd day of May 2019 (the "Fifth Amendment Effective Date")
SEPARATION AGREEMENT AND RELEASESeparation Agreement • March 20th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledMarch 20th, 2020 Company Industry JurisdictionThis Separation Agreement and Release (“Agreement”) is made between Orchard Therapeutics plc (the “Parent”), Orchard Therapeutics North America, a California corporation (the “U.S. Subsidiary”) and Mark Rothera (the “Executive”). The Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates are collectively referred to herein as the “Company,” and the obligations of the Company set forth in this Agreement may be discharged by any entity within that definition. The Parent, the U.S. Subsidiary and the Executive are collectively referred to as the “Parties.”
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • January 24th, 2024 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJanuary 24th, 2024 Company Industry JurisdictionTHIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of December 15, 2023 (this “Agreement”), is entered into by and between Kyowa Kirin Co., Ltd., a Japanese joint stock company (kabushiki kaisha) (“Purchaser”), and Wilmington Savings Fund Society, FSB (the “Rights Agent”).
TRANSACTION AGREEMENT by and between KYOWA KIRIN CO., LTD. and ORCHARD THERAPEUTICS PLC Dated as of October 5, 2023Transaction Agreement • October 5th, 2023 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 5th, 2023 Company Industry JurisdictionThis TRANSACTION AGREEMENT (this “Agreement”), dated as of October 5, 2023, is by and between Kyowa Kirin Co., Ltd., a Japanese joint stock company (kabushiki kaisha) (“Purchaser”) and Orchard Therapeutics plc, a public limited company incorporated under the laws of England and Wales with registered number 11494381 (“Apple” and, together with Purchaser the “Parties”). All capitalized terms used in this Agreement shall have the meanings ascribed to such terms in Annex A or as otherwise defined elsewhere in this Agreement.